February 10, 2020
An anti-cancer compound developed at the University of Michigan has shown “profound” activity in mouse models against two subtypes of leukemia — representing up to 40% of patients — a U-M research team reports in the Journal of Clinical Investigation. The compound, dubbed MI-3454, inhibits the protein-protein interaction between menin and Mixed Lineage […]
